Biotech stocks are back in the news lately. While Gilead Sciences (GILD) has not been a leader this year, it has led bull runs in the past. Thus, let’s focus on a broken wing butterfly trade in GILD stock. ↑ X NOW PLAYING 450% William O’Neil Winner Profited Off Of This Significant Medical Sector Innovation […]
Gilead Sciences (GILD) came up with a mixed fourth quarter late Tuesday as sales of its Covid treatment, Veklury, bolstered sales. But earnings ended up light and undercut GILD stock. X During the December quarter, Gilead earned an adjusted $1.72 per share on $7.12 billion in total revenue. Earnings increased 3% year over year, but […]
Gilead Sciences (GILD) said Monday its drug, Trodelvy, failed to pass muster in a study of patients with a common form of lung cancer, and GILD stock toppled.